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phosphate cytidylyltransferase (PF13_0253)—
also correlate with parasite survival in two
other P. falciparum strains (Fig. 2B, black ar-
rows, and table S4). The GB4 SNP alleles are
shared with the NF54 and 3D7 strains that also
survive, and the 7G8 SNP alleles are shared with
the SL strain that is melanized by the R strain
(7). Five genes were selected as top candidates
for detailed genetic analysis on the basis of large
differences in gene expression and/or on poly-
morphisms that correlates with survival in other
strains (table S5).
Two top candidate genes, Pfs47 and Pfs48/
45, code for members of the 6-cysteine protein
family that are expressed on the gametocyte sur-
face. Previous gene disruption experiments in the
NF54 line revealed that Pfs48/45 is critical for
gamete fertility (12).Pfs47 is expressed in female
gametocytes but is not essential for P. falciparum
fertilization, although its homolog in Plasmodium
berghei is required for female gamete fertility
(12, 13). The intensity of infectionwith thePfs48/45
knockout (KO) line (NF54 genetic background) in
the R strain was low, probably because of reduced
fertility. However, those parasites that invaded the
midgut had a similar phenotype as wild-type (WT)
NF54 parasites (8), and only 3% were melanized
(fig. S4), indicating that Pfs48/45 is not required
to evade the mosquito immune system. In contrast,
Pfs47 KO (NF54 genetic background) parasites
develop and invade the midgut but are eliminated
by R mosquitoes (99% melanization) (Fig. 3A);
although Pfs47 KO parasites are not melanized
by S mosquitoes (Fig. 3A), the infection level in
the S strain (median of one oocyst per midgut) is
much lower than that in A. stephensi mosquitoes
(60 oocysts per midgut median) (fig. S5). This
A. stephensi strain has been selected to be highly
permissive to P. falciparum infection (14).
To determine whether Pfs47 interacts with
the mosquito immune system, we disrupted the
A. gambiae complement-like system by silencing
TEP1. Reducing TEP1 expression completely re-
versed melanization of Pfs47 KO parasites in the
R strain (Fig. 3B). In the A. gambiae S strain (G3),
neither NF54 WT nor Pfs47 KO parasites were
melanized (Fig. 3C); although TEP1 silencing had
no significant effect on infection with NF54WT
parasites (Fig. 3C), it increased both the intensity
(P < 0.0001, Mann-Whitney test) and the prev-
alence of infection (P < 0.001; c2 test) of Pfs47
KO parasites (Fig. 3C). This result indicates that
Pfs47 is necessary for P. falciparum parasites to
evade two well-characterized immune responses
mediated by TEP1 inA. gambiae: killing followed
by melanization in the R strain and parasite lysis
without melanization in the S strain.
Pfs47 protein is present on the surface of WT
NF54 ookinetes, the stage that invades themidgut,
but is absent in Pfs47 KO parasites (Fig. 3D). The
expression of HPX2 and NOX5, two enzymes that
mediate midgut nitration in response to P. berghei
infection and promote TEP1 activation (2), was
evaluated in S mosquitoes. HPX2 and NOX5 were
not induced by NF54WT parasites, and nitration
levels were lower than in uninfected controls
(Fig. 3E). In contrast, Pfs47 KO parasites induced
expression of HPX2 and NOX5 and a robust nitra-
tion response, indicating that Pfs47 may prevent
TEP1-mediated lysis by suppressing midgut epi-
thelial nitration responses (Fig. 3E).
Finally, we confirmed the importance ofPfs47
for parasite survival by complementing the Pfs47
KO linewith differentPfs47 alleles (figs. S6 to S9).
As expected, the NF54 allele of Pfs47 reversed the
melanization phenotype (0% melanization) in the
R strain when the complemented parasites were
kept under sustained drug pressure, confirming
that this allele of Pfs47 is sufficient to evade the
immune system (Fig. 4A). A reversal to a mixed
live/melanization phenotype was observed when
the drug pressure was reduced (fig. S10). In con-
trast, complementation with the 7G8 allele failed
to rescue parasites in the R strain, because 99%
melanization was observed (Fig. 4B).
Together, our findings identify Pfs47 as an
essential survival factor for P. falciparum that al-
lows the parasite to evade the immune system of
A. gambiae, a major mosquito vector in Africa.
However, other parasite genes may also be in-
volved in this process. Pfs47 is a highly poly-
morphic gene with a marked population structure
in field isolates and exhibits extreme fixation in
non-African regions of the world (15, 16). Our
findings suggest that the population structure of
Pfs47 may be due to adaptation of P. falciparum
to the different Anopheles vector species present
outside of Africa. The fact that the 7G8 allele of
Pfs47 is sufficient to evade the TEP1 complement-
like system in S mosquitoes but not in the R
strain indicates that there are also genetic differ-
ences in the vector that determine compatibility
with parasites that express specific Pfs47 al-
leles. It appears that Pfs47 evolved a function in
P. falciparum that increases parasite survival in
A. gambiaemosquitoes and may be responsible,
at least in part, for the very high rates of malaria
transmission in hyperendemic regions in Africa.
Disruption of the immunomodulatory activity of
Pfs47 may prove to be an effective strategy to
reduce malaria transmission to humans.
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Tetrahydrobiopterin Biosynthesis as
an Off-Target of Sulfa Drugs
Hirohito Haruki,1 Miriam Grønlund Pedersen,1 Katarzyna Irena Gorska,1
Florence Pojer,2 Kai Johnsson1*
The introduction of sulfa drugs for the chemotherapy of bacterial infections in 1935 revolutionized medicine.
Although their mechanism of action is understood, the molecular bases for most of their side effects remain
obscure. Here, we report that sulfamethoxazole and other sulfa drugs interfere with tetrahydrobiopterin
biosynthesis through inhibition of sepiapterin reductase. Crystal structures of sepiapterin reductase with
bound sulfa drugs reveal how structurally diverse sulfa drugs achieve specific inhibition of the enzyme. The
effect of sulfa drugs on tetrahydrobiopterin-dependent neurotransmitter biosynthesis in cell-based assays
provides a rationale for some of their central nervous system–related side effects, particularly in high-dose
sulfamethoxazole therapy of Pneumocystis pneumonia. Our findings reveal an unexpected aspect of the
pharmacology of sulfa drugs and might translate into their improved medical use.
Tetrahydrobiopterin (BH4) is a cofactor ofaromatic hydroxylases, such as phenyl-alanine, tyrosine and tryptophan hydrox- ylases, all isoforms of nitric oxide synthases,and alkylglycerol monooxygenase (1). BH4deficiencies result in symptoms of hyperphenyl-
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alaninemia, as well as dopamine and serotonin
(5-hydroxytryptamine) deficiencies (2, 3). The
final step in BH4 biosynthesis is the reduction
of 6-pyruvoyltetrahydropterin by sepiapterin re-
ductase (SPR) (Fig. 1A). BH4 is also recycled
from the oxidized form of the cofactor and syn-
thesized by a salvage pathway via dihydrobiop-
terin (BH2) (Fig. 1A). Recently, we showed that
the anti-inflammatory drug sulfasalazine and its
metabolite sulfapyridine are potent inhibitors of
SPR and proposed that an inhibition of BH4 bio-
synthesis by the highly permeable sulfapyridine
is responsible for the anti-inflammatory activity
of sulfasalazine in rheumatoid arthritis (4). Here,
we report that the inhibition of BH4 biosynthesis
contributes to the pharmacological properties of
other clinically approved drugs. By screening a
library of approved drugs for SPR inhibitors, we
identified 10 drugs that inhibited SPR with me-
dian inhibitory concentration (IC50) values below
100 nM (Fig. 1B and tables S1 and S2). These
included the known SPR inhibitors sulfasalazine
and sulfapyridine. Furthermore, the antibacterial
sulfa drugs—sulfathiazole, sulfamethoxazole, sulfa-
methizole, phtalylsulfathiazole, and sulfadiazine,
as well as the three antidiabetic sulfonylureas
chlorpropamide, glibenclamide, and tolbutamide—
were identified as potent SPR inhibitors. To gain an
understanding of the binding mode of the different
sulfonamides to SPR, we solved the crystal
structures of SPR with bound nicotinamide
adenine dinucleotide phosphate (NADP+) and
sulfapyridine or sulfathiazole. SPR, NADP+, and
sulfapyridine or sulfathiazole form a ternary
complex in which the sulfa drugs block the
substrate binding site (Fig. 2, A and B). The two
drugs bind to SPR in a near-identical fashion
(Fig. 2B), and there are no substantial differences
detectable between the two protein structures
(root-mean-square deviation between backbone
Ca atoms of 0.1 Å). The sulfonamide, the moiety
common to all hits, and the nitrogen atom in the
heteroaromatic ring of sulfapyridine and sulfa-
thiazole form specific hydrogen bonds with ac-
tive site residues Ser157, Tyr170, and Asp257 (Fig.
2C). A hydrogen bond acceptor at a position
equivalent to that of the nitrogen atom in the
pyridine ring of sulfapyridine is found in all
identified SPR inhibitors (Fig. 1B); in the sul-
fonylureas, the oxygen atom of the urea group
could function as a hydrogen bond acceptor.
Previous structural studies on mouse SPR have
revealed that these three residues are important
for substrate binding (5). The pyridine or thiazole
rings also stack on top of the nicotinamide ring
of NADP+ (Fig. 2B) and make hydrophobic con-
tacts with residues Leu104, Trp167, Met205, and
Ala209. The different heterocycles or alkyl groups
found in other SPR inhibitors (Fig. 1B) should
be able to bind in an equivalent fashion as the
heteroaromatic ring of sulfapyridine and sulfa-
thiazole. Our structural data thus suggest how
structurally diverse sulfonamides achieve inhi-
bition of SPR but also why certain sulfa drugs,
such as sulfamethazine (Fig. 1B), are only very
weak inhibitors of SPR. Sulfamethazine is a
weaker inhibitor of SPR than sulfadiazine, which
is 370 times as strong, although it differs from
1École Polytechnique Fédérale de Lausanne (EPFL), Institute of
Chemical Sciences and Engineering, Institute of Bioengineering,
National Centre of Competence in Research (NCCR) in Chemical
Biology, 1015 Lausanne, Switzerland. 2EPFL, Global Health
Institute, 1015 Lausanne, Switzerland.
*Corresponding author. E-mail: kai.johnsson@epfl.ch
Fig. 1. Pathways for BH4 homeostasis and structures of SPR inhibitors. (A) BH4 biosynthetic
pathways. SPR catalyzes formation of BH4 from 6-pyruvoyltetrahydropterin and of BH2 from sepiapterin in
a salvage pathway. (B) SPR inhibitors, their IC50 values for inhibition of SPR in an enzymatic assay, and
some of their pharmacokinetic properties. IC50 values are means of triplicate experiments (N = 2 at least)
(full data in table S2). The benzenesulfonamide moiety found in all SPR inhibitors is highlighted in red.
Average steady-state serum or blood concentrations (Css) at therapeutic dose and the ratio of CSF-to-
blood concentrations are literature values (see references in table S3). The listed ratio of CSF-to-blood
concentration of tolbutamide was determined in rats (26, 27). Sulfamethazine, which only weakly inhibits
SPR, served as negative control throughout this work. n.a., not available.
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sulfadiazine only by two additional methyl groups
attached to the pyrimidine ring (Fig. 1B). Aman-
ual superimposition of sulfamethazine on sulfa-
pyridine in the structure of SPR reveals an
energetically unfavorable interaction of the two
additional methyl groups with the side chains
of Met205 and Gln206, respectively; the distance
of the sulfur atom of Met205 and the amide ni-
trogen of Gln206 to the nearest methyl group is
2.55Å and 2.75Å, respectively (fig. S1, D and E).
These distances are more than 0.5 Å below the
corresponding nonbonded contact distances ob-
served in organic crystals and protein structures
(6, 7).
Next, we examined if these drugs reduce
BH4 levels in human primary dermal fibroblasts
in which BH4 biosynthesis is induced by pro-
inflammatory cytokines. Incubation of human
fibroblasts with interferon-g (IFN-g) and tumor
necrosis factor–a (TNFa) for 24 hours increased
BH4 levels 165-fold to 0.33 nmol/mg protein
(Fig. 3A). SPR inhibitors decreased BH4 levels
in cytokine-stimulated fibroblasts in a dose-
dependent manner, whereas sulfamethazine had
no effect on BH4 levels. Dihydroneopterin tri-
phosphate (DHNTP) is a precursor of the SPR
substrate 6-pyruvoyltetrahydropterin in the bio-
synthesis of BH4 (Fig. 1A), and increased DHNTP
levels have been detected in cytokine-stimulated
fibroblasts derived from SPR-deficient patients
(8). Accordingly, treatment with SPR inhibitors
significantly increased DHNTP levels (measured
as neopterin after phosphatase treatment) (Fig. 3A
and Fig. 1A), which confirmed that the observed
decrease in BH4 is due to an inhibition of SPR.
Note that, the observed inhibition of BH4 bio-
synthesis occurs at drug concentrations that are
within their reported serum levels (Fig. 1B). The
exception in these experiments was sulfasalazine,
which decreased BH4 levels only at high micro-
molar concentrations and mainly by inhibition of
cytokine signaling (fig. S2). The low potency of
sulfasalazine as SPR inhibitor in cell-based assays
can be attributed to its low cell permeability (9).
Fig. 2. Binding mode of sulfa drugs to SPR. (A) Overview of crystal structure of human SPR in
complex with NADP+ (green) and sulfapyridine (magenta). (B) Close-up of a 2.4 Å crystal structure of
human SPR with bound NADP+ and sulfapyridine. In the ternary complex, the pyridine ring of
sulfapyridine is stacked on top of the nicotinamide ring of NADP+ with a distance of 3.3 Å between
the nitrogen in the pyridine ring and C4 of the nicotinamide ring. The overlay of sulfapyridine with
sulfathiazole (orange) from a 2.45 Å crystal structure of human SPR with bound NADP+ and sulfathiazole
shows that the two drugs bind to SPR in a near-identical fashion. (C) Key hydrogen bonds between the
sulfonamide moiety of sulfapyridine and active site residues Ser157, Tyr170, and Asp257 known to be
important for substrate binding (5). A water molecule (red) mediates the hydrogen bond between
Asp257 and sulfapyridine. Distances are given in Å.
Fig. 3. Inhibition of
BH4and L-dopasynthe-
sis by sulfonamides.
(A) Effect of selected
drugs on BH4 synthesis
in cytokine-stimulated
human primary dermal
fibroblasts. Intracellular
BH4 and neopterin lev-
els were measured after
24 hours concomitant
treatment of IFN-g and
TNFa and SPR inhibitors
(0.01, 0.1, and 1 mM).
Data are means T SD
from triplicate experi-
ments [N = 1, except N =
3 for dimethyl sulfoxide
(DMSO) + cytokines]. (B)
Effect of selected drugs
on BH4 and extracellular
3-MT levels in SK-N-BE(2)
cells. Cells were incubated
with drugs for 24 hours at 200 mM concentrations. Intracellular BH4 level
and 3-MT level in culture supernatant were measured. Data are means T SD
from triplicate experiments (N = 1). (C) Effect of sulfamethoxazole (SMX),
sulfathiazole (STZ), and sulfapyridine (SP) on BH4 synthesis and L-dopa levels
in SK-N-BE(2) cells. Intracellular BH4 levels were measured after 24-hour
treatment of cells with drugs. Extracellular L-dopa levels were measured after
24-hour treatment of cells with drugs, followed by 30 min of treatment with
10 mM NSD-1015, aromatic L-amino acid decarboxylase inhibitor. Data are
means T SD from triplicate experiments (N = 1, 2, 3 for STZ, SP, and SMX,
respectively).
www.sciencemag.org SCIENCE VOL 340 24 MAY 2013 989
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Sulfamethoxazole is currently the most-used
sulfa drug and is prescribed in combination
with trimethoprim (cotrimoxazole) for micro-
bial infections and as standard treatment against
Pneumocystis pneumonia (PCP), a prevalent op-
portunistic fungal infection in immunocompro-
mised individuals (10, 11). Both sulfamethoxazole
and trimethoprim target pathogen tetrahydro-
folate synthesis; sulfamethoxazole is a compet-
itive inhibitor of dihydropteroate synthase, whereas
trimethoprim inhibits dihydrofolate reductase
(DHFR). Adverse effects of sulfamethoxazole-
trimethoprim at standard dose for bacterial in-
fection are relatively rare, but CNS-related side
effects are frequently observed at the higher
therapeutic dose used in PCP (up to 100 mg/kg
of body weight per day sulfamethoxazole and
20 mg/kg per day of trimethoprim). These in-
clude anorexia, nausea, headache, nervousness,
fine tremors, lightheadedness, insomnia, and
drowsiness (see table S4 for a compilation of re-
ports concerning CNS-related adverse effects).
For example, administering 100 mg/kg per day
of sulfamethoxazole to 12 healthy adults resulted
in CNS-related adverse effects in all subjects
within 3 days (12). Furthermore, recent analyses
of clinical data of PCP patients indicate that high-
dose sulfamethoxazole-trimethoprim therapy can
cause psychosis; the reported incidence being
12 to 20% (13, 14). Nausea, vomiting, and CNS-
related symptoms are common, dose-dependent
adverse effects of most sulfa drugs (15–17). In
sulfasalazine treatment, these symptoms are
correlated with serum concentrations of sulfa-
pyridine but not sulfasalazine (18). In dogs, which
exhibit CNS-related side effects similar to those
of humans (19), complete gastrointestinal evis-
ceration or direct application of sulfapyridine
to the vomiting center showed that nausea and
vomiting are not caused by direct action of the
drug on the gastrointestinal tract or the vomiting
center (20). The inhibition of BH4 biosynthesis
by sulfa drugs and a subsequent inhibition of
neurotransmitter biosynthesis could provide a
rationale for their CNS-related side effects. This
hypothesis is supported by the observation that
the adverse effects of sulfamethoxazole resemble
the symptoms of genetically inherited SPR de-
ficiency. Basal levels of BH4 in SPR deficiency
in most tissues are maintained through salvage
or alternative pathways (Fig. 1A). An exception
is the brain, where the low expression level of the
enzymes involved in salvage pathways, such as
DHFR, diminishes their efficiency. Symptoms of
SPR deficiency are those of catecholamine and
serotonin deficiencies with disabling motor and
cognitive deficits (2). Furthermore, recurrent
vomiting is a gastrointestinal symptom of SPR
deficiency (2). SPR deficiency can be most re-
liably diagnosed through analysis of cerebro-
spinal fluid (CSF); CSF concentrations of BH2
and sepiapterin in SPR deficiency are signifi-
cantly increased whereas those of dopamine and
serotonin metabolites are decreased (2). An effect
of sulfamethoxazole-trimethoprim on biopterin
levels in CSF has been reported previously:
Patients with Machado-Joseph disease, an auto-
somal dominantly inherited neurodegenerative
disorder,whowere administered sulfamethoxazole-
trimethoprim (400 mg sulfamethoxazole, 80 mg
trimethoprim, twice daily) showed significantly
increased BH2 levels in CSF (21). Dopamine in-
sufficiency has been reported in a child with di-
hydropteridine reductase (DHPR) deficiency after
being given sulfamethoxazole-trimethoprim (22).
DHPR is involved in recycling of BH4 (Fig. 1A),
and the observed dopamine insufficiency could
be explained by a further depletion of already
decreased BH4 levels through inhibition of SPR.
To demonstrate that sulfa drugs can lower
neurotransmitter levels through depletion of BH4,
we investigated whether sulfa drugs in cell cul-
ture experiments would affect catecholamine bio-
synthesis in the human neuroblastoma cell line
SK-N-BE(2) (23). SK-N-BE(2) cells have con-
stitutively high levels of BH4 and excrete sub-
stantial amounts of the dopamine metabolite
3-methoxytyramine (3-MT). The identified SPR
inhibitors, with the exception of sulfasalazine, at
200 mM, decreased intracellular BH4 and extra-
cellular 3-MT levels (Fig. 3B). The activities in
this cellular assay, again with the exception of
sulfasalazine, correlated well with the IC50 values
measured in the enzymatic assay (Figs. 1B and
3B). For more detailed analysis, SK-N-BE(2)
cells were incubated with varying concentrations
of sulfathiazole, sulfamethoxazole, or sulfa-
pyridine; the drugs decreased BH4 levels from
0.3 to 0.05 nmol/mg protein, with IC50 values
of 23, 59, and 201 mM, respectively (Fig. 3C).
To examine tyrosine hydroxylase activity in
drug-treated cells, extracellular L-dopa levels were
measured after 24 hours of treatment with sul-
fathiazole, sulfamethoxazole, or sulfapyridine
(Fig. 3C) (24). In these experiments, sulfa-
methoxazole, sulfathiazole, and sulfapyridine
decreased L-dopa levels with IC50 values of 31,
63, and 143 mM, respectively. In conclusion,
sulfa drugs at concentrations below their serum
levels interfere with catecholamine biosynthesis
through BH4 depletion. We assume that similar
effects will be observed on serotonin biosynthesis.
Our findings, together with ample clinical
observations, suggest that inhibition of BH4 bio-
synthesis by sulfa drugs is responsible for some
of their CNS-related side effects. The incidence
of these side effects will depend on the inhibitory
activity of the sulfa drug toward SPR—its serum
concentration during therapy, aswell as its uptake
into the CNS. Sulfamethoxazole reaches plasma
levels of up to 600 mM, shows good uptake into
the CNS, and is a potent inhibitor of SPR in
cellular assays (Fig. 1B and Fig. 3); we therefore
conclude that sulfamethoxazole at these doses
will affect BH4 and catecholamine biosynthesis
in the brain. The excellent CNS uptake of sulfa-
pyridine and its good inhibitory activity against
SPR explain why its CNS-related side effects are
already observed at lower serum concentrations
compared with other sulfa drugs also inhibiting
SPR (i.e., sulfadiazine). Furthermore, sulfa drugs
not inhibiting SPR also show diminished CNS-
related side effects. In early studies on the efficacy
of sulfamethazine in treatment of labor pneumonia
(73 patients), it was noted that “The striking dif-
ference, however, was that the patients never com-
plained of the severe mental and physical depression
which often accompanies sulfapyridine treatment”
(25). CNS-related side effects have not been pub-
lished for first-generation sulfonylureas tolbuta-
mide and chlorpropamide and second-generation
sulfonylurea glibenclamide. The effective serum
concentration of glibenclamide is too low for SPR
inhibition (Fig. 1B). However, the serum concen-
trations of tolbutamide and chlorpropamide are
comparable to thosemeasured for sulfa drugs.We
assume that low CNS uptake of these drugs is
responsible for the absence of such side effects.
In fact, tolbutamide uptake in rat CNS is ex-
tremely low compared with other drugs (26, 27).
Sulfa drugs were the scaffold for the de-
velopment of multiple other drugs (28). Proteins
that are targeted by such drugs—for example,
carbonic anhydrase and endothelin receptor—are
therefore possible off-targets of sulfa drugs, and
some carbonic anhydrase inhibitors (sultiame)
or endothelin receptor antagonists (sitaxentan)
cause side effects such as headache and dizziness.
We could not observe inhibition of human car-
bonic anhydrase II, a representative isozyme
of carbonic anhydrases, by sulfa drugs (IC50 >
1 mM in an enzymatic assay) (table S6). Sulfa-
methoxazole and sulfathiazole were reported to
competewith endothelin-1 for binding to endothelin
receptor type A with IC50 values that are within
their therapeutic serum concentrations, but in func-
tional assays sulfamethoxazole did not show ac-
tivity at the highest concentrations tested (100 mM)
(table S7). These observations allow us to rule
out carbonic anhydrase II but not endothelin re-
ceptor as potential additional off-targets. More
generally speaking, our results do not exclude the
presence of other off-targets of sulfa drugs.
Our finding that sulfa drugs interfere with
BH4-dependent neurotransmitter biosynthesis also
suggests strategies for a potential improvement
of PCP therapy. L-Dopa or 5-hydroxytryptophan,
which are successfully used as supplements in
SPR deficiency (2), might dampen some of their
CNS-related side effects in high-dose sulfameth-
oxazole therapy. Second, sulfa drugs displaying
no, or weak, SPR inhibition should be consid-
ered as alternatives to sulfamethoxazole (29).
In summary, the identification of sulfa drugs as
inhibitors of BH4 biosynthesis is of relevance
for understanding the history of sulfa drugs and
has direct implications for their future use.
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Defining Single Molecular Forces
Required to Activate Integrin
and Notch Signaling
Xuefeng Wang1 and Taekjip Ha1,2*
Cell-cell and cell-matrix mechanical interactions through membrane receptors direct a wide
range of cellular functions and orchestrate the development of multicellular organisms. To define
the single molecular forces required to activate signaling through a ligand-receptor bond, we
developed the tension gauge tether (TGT) approach in which the ligand is immobilized to a surface
through a rupturable tether before receptor engagement. TGT serves as an autonomous gauge to
restrict the receptor-ligand tension. Using a range of tethers with tunable tension tolerances, we show
that cells apply a universal peak tension of about 40 piconewtons (pN) to single integrin-ligand
bonds during initial adhesion. We find that less than 12 pN is required to activate Notch receptors.
TGT can also provide a defined molecular mechanical cue to regulate cellular functions.
Cells sense and respond to the mechanicalproperties of the surrounding extracellu-lar matrix (ECM) and neighboring cells.
Reciprocally, cells also apply force on the ECM
and transmit mechanical signals to neighboring
cells. These mechanical interactions activate in-
tracellular signaling pathways and regulate such
diverse processes as cell adhesion, polarization,
migration, proliferation, and differentiation (1, 2).
As a result, by tuning bulk mechanical properties
like stiffness, texture, and geometry of the sub-
strate, researchers have gained insight into pro-
cesses such as stem cell differentiation (3) and
tumormetastasis (4). Single-molecule force spectros-
copy has been used to study various mechano-
sensitive membrane receptors, including integrin,
cadherin, and Notch (5–8). However, these ap-
proaches cannot reveal the single-molecule forces
required for physiological functions because they
either measure collective forces exerted through
manymolecules or probemolecular unbinding or
unfolding forces only. More recently, fluorescence
resonance energy transfer–based force sensorswere
developed and inserted to target sites to monitor
cellular forces (9, 10), but great efforts must be
taken to prepare the sensors and to track and in-
terpret the fluorescence signal. Here, we describe
a platform termed tension gauge tether (TGT) that
allows us to determine the single-molecule forces
required for mechanical signaling in cells.
In TGT, a ligand is covalently conjugated to a
tether that ruptures at a critical force, which we
term “tension tolerance” or Ttol, and is immobi-
lized on a solid surface through the tether (Fig. 1).
Cells are plated on the surface, and membrane
receptors engage with and apply tension to the
ligands. If signal activation through the receptor
requires a molecular tension larger than Ttol, the
tether will rupture, abolishing signal activation.
In contrast, if the required tension is smaller
than Ttol, the tether will endure, activating the
receptor-mediated signaling. By engineering a
series of tethers with different Ttol values, the ten-
sion required for signal activation can be deter-
mined by observing receptor-regulated cell activities,
which are usually much easier to detect than
single-molecule events. Because each ligand is
equipped with an individual tension gauge, the
measurement is independent of the receptor or
ligand density.
DNA is a good candidate for use as rupturable
tether in TGT because force application geometry
(fig. S1) strongly affects its rupture force, with
an unzipping force rupturing the DNA at a much
lower force than a shearing force (11, 12). Albrecht
et al. have exploited this feature to estimate the
rupture force of an antigen-antibody bond rela-
tive to the rupture forces of double-stranded
DNA (dsDNA) in unzipping or shear geometry
(13). The estimated rupture force of a 21–base
pair (bp) DNA is about 12 pN in the unzipping
geometry and is about 56 pN in the shear ge-
ometry (14). Intermediate rupture forces can be
obtained by applying forces through an internal
position on the DNA duplex, and the theoretical
Ttol values of the resulting tethers can be esti-
mated (Fig. 1D and fig. S2). Ttol represents the
force required to rupture the tether in less than 2 s
when the force is applied at a constant level (12)
[see supplementary text (14)].
Integrins are membrane receptors that medi-
ate cell adhesion and sense and transduce me-
chanical information from the ECM into cells.
Bulk traction forces applied through a collection
of integrin-ligand bonds have been extensively
examined (15–18). Here, we apply the TGT plat-
form to probe the tension on a single integrin-ECM
ligand bond required for cell adhesion (specifi-
cally, integrin aVb3 and its ligand, cyclic RGDfK
peptide). To reduce nonspecific adhesion, ligands
with the DNA tether are immobilized through an
Avidin-biotin linker on a glass surface passivated
with polyethylene glycol (PEG). The Avidin-
biotin unbinding force, ~160 pN (19), is much
larger than the tether rupture forces used here
(≤56 pN).
We conjugated RGDfK to nine different DNA
tethers with estimated Ttol values of 12, 16, 23,
33, 43, 50, 54, 55, and 56 pN (fig. S2). These
DNA tethers have various force application ge-
ometries but share the same length, sequence,
and thermal stability. ATGTarray was created by
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